Next Article in Journal
Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France
Previous Article in Journal
A Comparison of HAS & NICE Guidelines for the Economic Evaluation of Health Technologies in the Context of Their Respective National Health Care Systems and Cultural Environments
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Perspective

Conflict of Interest in Health Technology Assessment Decisions: Case Law in France and Impact on Reimbursement Decisions

by
Sandrine Frybourg
1,*,
Cécile Remuzat
1,
Åsa Kornfeld
1 and
Mondher Toumi
2
1
Creativ-Ceutical, Paris, France
2
Faculty of Medicine, Public Health Department Research Unit EA 3279, University Aix-Marseille Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2015, 3(1), 25682; https://doi.org/10.3402/jmahp.v3.25682
Submission received: 8 August 2014 / Revised: 5 May 2015 / Accepted: 26 June 2015 / Published: 9 December 2015

Abstract

The slow reaction of French authorities to the so-called Mediator® saga in 2009 in France led to investigations that questioned the way conflicts of interest are reported. France implemented the Loi Bertrand (‘Bertrand Law’) in May 2013, known as the ‘French Sunshine Act’, with the aim of specifying the scope of disclosure obligations. This policy research reviewed the Loi Bertrand and reported case law from the French Council of State (COS) related to conflicts of interest in French Health technology assessment (HTA) opinion. The Loi Bertrand requires the publication of most of the agreements concluded between health-care professionals and companies and covers a vast range of health products. Commercial sales agreements of goods and services concluded between manufacturers and health-care professionals are a strong exception to this disclosure obligation. Six cases examined by the COS were analyzed, most of them related to the publication of guidelines or the removal of products from the list of reimbursed drugs and devices. These cases have been reviewed, as well as the impact of the ruling on reimbursement decisions. Four cases led to suspension or invalidation of decisions based on the Haute Autorité de Santé (HAS) recommendations due to conflicts of interest. In the two other cases, the HAS provided post hoc declarations of interest when required by the COS, and the COS considered the conflicts of interest as irrelevant for the decision. It appears that the COS based its decisions on two main criteria: the acknowledgement of negative conflicts of interest (a link with competitors) and the absence of declarations of conflicts of interest, which have to be presented when required by legal authorities irrespective of when they were completed (even posterior to the HAS opinion). However, the number of cases that have been decided against the HAS remains very limited with respect to the volume of assessments performed yearly. The strengthening of the regulation on declarations of interest might lead to more transparency but also to more cases decided by the COS. A new press investigation (in March 2015) related to alleged cases of conflict of interests led policy makers to amend the Bertrand Law in April 2015 and require the disclosure of amounts paid to health-care professionals by the industry.
Keywords: conflict of interest; Sunshine Act; Loi Bertrand; HAS; Council of State; HTA conflict of interest; Sunshine Act; Loi Bertrand; HAS; Council of State; HTA

Share and Cite

MDPI and ACS Style

Frybourg, S.; Remuzat, C.; Kornfeld, Å.; Toumi, M. Conflict of Interest in Health Technology Assessment Decisions: Case Law in France and Impact on Reimbursement Decisions. J. Mark. Access Health Policy 2015, 3, 25682. https://doi.org/10.3402/jmahp.v3.25682

AMA Style

Frybourg S, Remuzat C, Kornfeld Å, Toumi M. Conflict of Interest in Health Technology Assessment Decisions: Case Law in France and Impact on Reimbursement Decisions. Journal of Market Access & Health Policy. 2015; 3(1):25682. https://doi.org/10.3402/jmahp.v3.25682

Chicago/Turabian Style

Frybourg, Sandrine, Cécile Remuzat, Åsa Kornfeld, and Mondher Toumi. 2015. "Conflict of Interest in Health Technology Assessment Decisions: Case Law in France and Impact on Reimbursement Decisions" Journal of Market Access & Health Policy 3, no. 1: 25682. https://doi.org/10.3402/jmahp.v3.25682

APA Style

Frybourg, S., Remuzat, C., Kornfeld, Å., & Toumi, M. (2015). Conflict of Interest in Health Technology Assessment Decisions: Case Law in France and Impact on Reimbursement Decisions. Journal of Market Access & Health Policy, 3(1), 25682. https://doi.org/10.3402/jmahp.v3.25682

Article Metrics

Back to TopTop